Wegovy oral or injection: what's different, what's the same, and how to choose

Step 1, understand the two routes before you decide anything

The weekly injection (the pen most people picture when they hear Wegovy) is a pre-filled device you inject under the skin, typically into the abdomen, thigh, or upper arm. Treatment starts at 0.25mg and the prescriber titrates upward, roughly every four weeks, through 0.5mg, 1.0mg, and 1.7mg, up to a standard maintenance dose of 2.4mg. The MHRA also approved a higher 7.2mg maintenance dose, with a dedicated single-dose pen confirmed on 14 April 2026, for adults with a BMI of 30 or above. Storage is in a refrigerator at 2–8°C; details on any room-temperature window are in the Patient Information Leaflet.

The tablet route is newer and works differently at the absorption stage. Semaglutide is poorly absorbed through the gut wall on its own, so the tablet pairs it with an absorption enhancer called SNAC. The result is a 1.5mg starting dose, titrating through 4mg and 9mg to a 25mg maintenance dose, taken once daily. No injection, no pen, no sharps. The trade-off is timing: it goes down first thing in the morning on an empty stomach, with a small amount of plain water, and you wait at least 30 minutes before food, coffee, or other oral medicines. For plenty of people, that fits naturally into the period before the kettle has even boiled.

Understanding that sequence matters before choosing. If you are still working out whether Wegovy comes as pills or an injection, the injection is forgiving about time of day while the tablet demands a consistent morning routine. Neither is objectively harder, they suit different lives.

Step 2, weigh up what the trial evidence actually says

Comparing the injection and tablet directly is tricky because the trials differed in length, population, and design. The STEP 1 trial of the 2.4mg injection ran for 68 weeks and reported an average body-weight reduction of around 15% versus placebo, as published in the New England Journal of Medicine. The OASIS 4 trial of the tablet ran for 64 weeks in 307 adults with obesity or overweight plus at least one weight-related condition, and reported around 13.6% average weight loss, rising to roughly 17% among participants who adhered fully throughout the study. That 17% figure is specific to full adherence, and it would be misleading to quote it as a typical outcome.

You can read more about how the tablet and injection figures compare on our oral vs injection effectiveness page, which works through the trial details more carefully. The short version: the injection has a modest edge in average results across the published data, but the gap narrows meaningfully for adherent tablet users, and average figures mask a wide range of individual responses. A fuller breakdown of the semaglutide forms is on our semaglutide tablets vs injection page.

Side effects are broadly similar across both forms: nausea, loose stools, constipation, indigestion and fatigue are most commonly reported, and they tend to cluster around dose increases. The NHS medicines information for semaglutide covers this in full detail and is worth reading before you start either form.

Step 3, consider which form a prescriber is likely to discuss with you

The NHS guidance on semaglutide covers both licensed forms, and a prescriber will look at several practical factors: whether you have needle anxiety or a condition affecting injection sites; your morning routine and whether a 30-minute fasting window is manageable daily; whether you take other oral medicines that need to be separated from the tablet; and your BMI and medical history. The injection's 7.2mg dose is licensed only for adults with a BMI of 30 or above; the tablet's licensing covers BMI 30 and above, or 27–29.9 with at least one weight-related condition.

There is no right answer independent of your situation. Some people find the idea of a weekly injection far preferable to a daily routine they have to get exactly right every morning. Others are glad to avoid injections entirely and find the tablet straightforward, and our page covering whether Wegovy is a pill or an injection explains the distinction in plain terms for anyone coming to this fresh. The semaglutide oral vs injection page goes into the practical comparison in more depth, and our treatment overview explains how both fit within the broader options available at nume.

If cost is part of the decision, our Wegovy tablet cost page sets out what private treatment typically involves. Both forms require an ongoing clinical relationship, a prescriber reviews your case before every repeat, not just at the start.

Step 4, getting a prescription through a regulated route

Wegovy in either form is a prescription-only medicine. There is no legal route to either the injection or the tablet in the UK without a valid prescription from a registered prescriber following a clinical assessment. That assessment exists for good reason: semaglutide is not suitable for everyone, and the form, the starting dose, and the titration plan should reflect your health history, current medicines, and circumstances.

At nume, consultations are reviewed personally by a GPhC-registered Independent Prescriber the same day, your answers are read by a clinician, not processed by software. The pharmacy holds GPhC registration number 9012878, verifiable on the GPhC register. Medicines are sourced through the licensed UK supply chain. If you order before noon on a working day and are clinically approved, treatment is dispatched the same day and delivered free by DPD the next working day, in plain unbranded packaging. There are no subscriptions and no hidden charges, the price on our treatment page covers consultation, prescription, and delivery.

Questions about the process are answered on our FAQs page, and our clinical team profile is at prescriber profile. If you want to talk through which form might suit you, speaking to our prescribers is the right next step.